A Pivotal Trial of ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Next Previous
Trial Profile

A Pivotal Trial of ARQ 087 in Subjects With FGFR2 Gene Fusion Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2018

At a glance

  • Drugs Derazantinib (Primary)
  • Indications Cholangiocarcinoma
  • Focus Registrational; Therapeutic Use
  • Sponsors ArQule; Basilea Pharmaceutica

    • Most Recent Events

    • 17 Apr 2018 According to an ArQule media release, the company has entered into an agreement with Basilea Pharmaceutica, under which Basilea will continue this trial further and will be responsible to develop and commercialize derazantinib in the US, EU, Japan and rest of the world excluding the People's Republic of China, Hong Kong, Macau and Taiwan.
    • 05 Mar 2018 According to an ArQule media release, the company is planning to complete dosing of patients needed to conduct interim analysis in this trial in 2018.
    • 21 Nov 2017 According to an ArQule media release, the company announced dosing of the initial four patients in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top